A Phase 1/2 interventional study of BIS-001ER in Focal Impaired Awareness Seizures, sponsored by Supernus Pharmaceuticals, Inc.. Active, not recruiting at 2 sites in Australia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-08-30.
Sponsored by Supernus Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Seizures with a site in Australia — 14 open to participants now, 20 under way, 12 of them phase 3. Seizures · Australia.
Among the 56 studies in Seizures with a site in Australia, this one is the 48th largest by planned enrollment of the 53 interventional ones that give a count, is one of 7 that started in 2018, is the only one in phase 1/2, reaches primary completion later than 4 of the 19 other live ones, and was the 23rd registered.
766 studies on the registry are indexed under Seizures; 134 are open to participants now.
Browse Seizures studies →14 of the 56 studies in Seizures with a site in Australia are open now. Recruiting first, the newest first:
Rapport Therapeutics Inc. · Sites in Australia, United States, Korea, Republic of
Ages 18–75
The POLG Foundation · Sites in Australia, United States, Denmark and 6 more countries
Rapport Therapeutics Inc. · Sites in Australia, United States, Korea, Republic of and 1 more country
Ages 18–75
Praxis Precision Medicines · Sites in Australia, United States, Spain
Ages 18–75
Supernus Pharmaceuticals, Inc. · Sites in Australia, United States, Bulgaria and 2 more countries
Ages 18–70
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 18 · Phase 3 32 · Phase 4 1
First in 2000; this study’s year is marked. 7 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 16 is below the median of 64 across 519 interventional studies indexed under Seizures.
Median enrollment 216 across the 53 interventional studies, 514 across the 2 observational. Of the 35 that completed or were terminated, 24 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
55 of 56 have an industry lead sponsor. The 10 most frequent:
Supernus Pharmaceuticals, Inc. is the lead sponsor of 64 studies on the registry; 6 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.
Supernus Pharmaceuticals, Inc. has 4 studies filed under Seizures — fewer than ten, so there is no comparison to draw.
8 of the studies in Seizures with a site in Australia that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT05219617Phase 3SK Life Science, Inc.Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults | 2027-02 |
| NCT02962414Phase 3Novartis PharmaceuticalsRoll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment | 2027-02-26 |
| NCT05077904Phase 3UCB Biopharma SRLA Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures | 2027-03-29 |
| NCT06908226Phase 3Longboard PharmaceuticalsA Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | 2027-11-11 |
Add all 8 to your calendar (.ics) → With an account.
Among the 56 studies in Seizures with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to examine safety signals and demonstrate seizure reduction in adults with FIAS treated with BIS-001ER as an add-on therapy in an in-patient and out-patient study design.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose administration for each participant will begin at 0.25mg b.i.d. escalating sequentially every 4 days to a maximum tolerated dose or target dose of 1.75mg b.i.d. Upon reaching the target dose or maximum tolerated dose, participants will maintain that dose for the balance of the 1 month out-patient titration period, after which they will begin a 96-hour in-patient video EEG monitoring treatment period.
Drug: BIS-001ER
BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.
Also known as: Huperzine A ER
Effect of BIS-001ER on Seizure Count
Reduction in average daily seizure count between baseline (pre-treatment) and evaluation (on treatment) video EEG monitoring periods.
Time frame: 6 Weeks
Effect of BIS-001ER on Percent Reduction in Daily Seizure Count
Percent reduction in average daily seizure count from the baseline VEM period compared to the evaluation video EEG monitoring period (on treatment).
Time frame: 6 Weeks
Effect of BIS-001ER on Seizure Count vs Titration Period (Diary)
Percent reduction in average number of seizures from the baseline period. (screening/retrospective diary) compared to the last week of the titration treatment period.
Time frame: 6 Weeks
Percent of Treatment Responders
Percent of participants considered treatment responders defined as those with a ≥25%, ≥50%, ≥75% reduction in seizures from the baseline VEM period compared to the VEM treatment evaluation period.
Time frame: 6 Weeks
Effect of BIS-001ER on Seizure Count During Extension Phase
Percent reduction of average number of seizures vs. baseline/retrospective diary at 1, 3, 6, 12 months during the extension period.
Time frame: 12 Months
Complete Seizure Protection
Proportion of subjects with 100% seizure reduction.
Time frame: 6 Weeks
Need for Rescue Medication
Proportion of subjects requiring rescue medication at different dosages.
Time frame: 6 Weeks
Started Apr 2018 (actual). Primary completion is estimated for Dec 2026, 104 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Supernus Pharmaceuticals, Inc. →